Genelux Corporation Common Stock Total Liabilities
Genelux Corporation Common Stock total liabilities. Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has total liabilities worth $9.45 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GNLX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genelux Corporation Common Stock (2019–2025)
Total liabilities of Genelux Corporation Common Stock from 2019 to 2025. This chart illustrates how Genelux Corporation Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore GNLX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Genelux Corporation Common Stock Competitors by Total Liabilities
The table below lists competitors of Genelux Corporation Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IF Bancorp Inc
NASDAQ:IROQ
|
USA | $743.01 Million |
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
USA | $1.93 Million |
|
Apetit Oyj
HE:APETIT
|
Finland | €37.60 Million |
|
DeFi Development Corp.
NASDAQ:DFDV
|
USA | $219.52 Million |
|
Paseco Co. Ltd
KQ:037070
|
Korea | ₩33.66 Billion |
|
Ampire Co Ltd
TWO:8049
|
Taiwan | NT$336.28 Million |
|
Bien Sparebank ASA
OL:BIEN
|
Norway | Nkr5.56 Billion |
|
Cj Corp Pref
KO:001045
|
Korea | ₩29.95 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down Genelux Corporation Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GNLX asset base.
Liquidity & Leverage Metrics
Genelux Corporation Common Stock Total Liabilities Ratios Explained
Genelux Corporation Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genelux Corporation Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual total liabilities of Genelux Corporation Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.48 Million | -11.36% |
| 2024-12-31 | $8.44 Million | +0.26% |
| 2023-12-31 | $8.42 Million | -79.62% |
| 2022-12-31 | $41.31 Million | +0.19% |
| 2021-12-31 | $41.24 Million | +12.48% |
| 2020-12-31 | $36.66 Million | +30.51% |
| 2019-12-31 | $28.09 Million | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more